Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh

Research (Published online: 04-12-2021)

10. Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh

Eaftekhar Ahmed Rana, Pronesh Dutta, Md. Sirazul Islam, Tanvir Ahmad Nizami, Tridip Das, Sharmin Chowdhury and Goutam Buddha Das

International Journal of One Health, 7(2): 220-226

ABSTRACT

Background and Aim: A vaccine program for coronavirus illness (coronavirus disease [COVID-19]) is currently underway in numerous regions of the world, including Bangladesh, but no health data on those who have been vaccinated are available at this time. The study aimed to investigate the health condition of people who had received their first dose of the Oxford- AstraZeneca vaccine and were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Materials and Methods: To detect SARS-CoV-2, a standard virological approach, real-time reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), was used. Several health indicators from vaccinated patients were collected using pre-structured questionnaires during the infection phase.

Results: A total of 6146 suspicious samples were analyzed, and 1752 were found to be positive for SARS-CoV-2, with 200 people receiving the first dose of the COVID-19 vaccine. One hundred and sixty-five (82.5%) were not hospitalized among the vaccinated people, and 177 (88.5%) did not have any respiratory problems. Only 8% of patients required further oxygen support, and 199 (99.5%) did not require intensive care unit intervention. Overall, oxygen saturation was recorded at around 96.8% and respiratory difficulties did not extend more than 5 days during the infection period. Among the vaccinated COVID-19-positive people, 113 (56.5%) and 111 (55.5%) had typical physiological taste and smell. Surprisingly, 129 (64.5%) people had diverse comorbidities, with high blood pressure (27.9%) and diabetes (32 [24.8%]) being the most common. The major conclusion of the current study was that 199 (99.5%) of vaccinated patients survived in good health and tested negative for RT-qPCR.

Conclusion: According to the findings of this study, administering the first dose of the Oxford-AstraZeneca vaccine considerably reduces health risks during the COVID-19 infection period.

Keywords: assessment, comorbidity, coronavirus disease, health risk, Oxford-AstraZeneca vaccine.